Sientra Updates Terms for Secondary Offering

The underwriters for this secondary offering are Piper Jaffray, Stifel, Leerink Partners and William Blair.

On November 3, 2014, the company completed an initial public offering (IPO), whereby it sold a total of 5.75 million shares of common stock at $15.00 per share, inclusive of 750,000 shares sold to underwriters pursuant to the exercise in full of their option to purchase additional shares. The company received net proceeds from the IPO of roughly $77.0 million.

This medical aesthetics company is committed to making a difference in patients’ lives by enhancing their body image, growing their self-esteem and restoring their confidence. It was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. It has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes.

Sientra sells breast implants and breast tissue expanders, or breast products, exclusively to board-certified and board-admissible plastic surgeons and tailor customer service offerings to their specific needs. These advantages have allowed it to increase its market share each year since it entered the market in 2012.

ALSO READ: Jefferies Starts Coverage on Biotechs: 3 Top Stocks to Buy Now

The company detailed its finances as:

We commenced sales of our breast implants in the United States in the second quarter of 2012. Our net sales were $44.7 million, $35.2 million and $10.4 million for the years ended December 31, 2014, 2013 and 2012, respectively. Our net sales were $26.6 million and $21.9 million for the six months ended June 30, 2015 and 2014, respectively. Our net loss was $5.8 million, $19.1 million and $23.4 million for the years ended December 31, 2014, 2013 and 2012, respectively. Our net loss was $6.4 million and $1.2 million for the six months ended June 30, 2015 and 2014, respectively.

Shares of Sientra traded up 2.9% at $22.65 Tuesday morning. The stock has a consensus analyst price target of $28.33 and a post-IPO trading range of $12.53 to $26.67.